October 5, 2026
Most MedTech hiring stories are about scale: an established product, a known buyer and a bigger territory to cover. A smaller group of US MedTech companies faces a harder problem. They are selling something the market has never bought before, which means there is no established referral pattern, no habit of use and, often, no clinician who has been trained on the technology.
In the first week of October 2026, three of these category creators made moves that show how they plan to solve that problem. On 1 October, Carlsmed, which makes AI-enabled personalised spine implants, appointed a 15-year Intuitive Surgical veteran as its first Chief Product and AI Officer, on the same day its new Medicare inpatient payment groups took effect. The same day, Mendaera launched its FDA-cleared handheld needle-guidance robot with Butterfly Network's Ultrasound-on-Chip imaging. And Neuromod, which treats tinnitus through ENT and audiology practices, named its new Chief Commercial Officer from Align Technology, the company behind Invisalign, and its new VP of Channel Development from Sonova.
Two of these moves are leadership hires, and both draw on companies that have already turned a new idea into an everyday part of clinical practice. The third is a commercial launch that shows the same challenge from a different angle. Together, they say a lot about where commercial hiring in US MedTech is heading: towards people who know how to build a market, not just sell into one.
On 1 October 2026, Carlsbad, California-based Carlsmed appointed Tony Jarc, Ph.D., to the newly created role of Chief Product and AI Officer. Jarc spent more than 15 years at Intuitive Surgical, most recently as Vice President, Digital Products and Machine Learning Insights, and built Intuitive's global AI organisation from the ground up. At Carlsmed he will lead the development and commercialisation of the company's next-generation technology platform, its surgical user interface and its personalised spine surgery procedures. He joins a leadership team that recently added Rich Heppenstall as CFO and promoted Jeff Bertolini to COO.
The appointment landed on the same day a significant reimbursement change took effect. Under the Centers for Medicare & Medicaid Services (CMS) FY2027 Hospital Inpatient Prospective Payment System final rule, all inpatient aprevo lumbar fusion procedures are now reimbursed under one of three newly created MS-DRGs: 523, 524 and 525, which cover extensive or complex spinal fusion procedures outside the cervical spine. Carlsmed expects the clearer DRG assignment and enhanced hospital reimbursement to accelerate hospital and patient access to aprevo.
Why hire from Intuitive? Intuitive is one of the clearest examples in MedTech of a company that turned a new way of operating into standard practice, and that relied on software, data and surgeon experience as much as on hardware. Carlsmed's chairman and CEO, Mike Cordonnier, described Jarc as a leader in deploying AI-enabled surgical technology at large scale. For a company whose product is a personalised implant planned for each patient, that matters: the surgeon experience, the planning workflow and the data behind it are all part of what is being sold.
The commercial lesson is that reimbursement removes a barrier but does not create demand on its own. Someone still has to show hospital value analysis committees and finance teams how the new DRGs work, and someone still has to win over spine surgeons one case at a time. As a result, personalised spine companies are likely to need spine sales representatives who can sell a planned, patient-specific procedure, clinical specialists who support surgeons through case planning, and reimbursement and health economics specialists who can translate a CMS rule into a hospital business case.
On 1 October 2026, Mendaera and Butterfly Network announced that Mendaera's FDA-cleared Focalist system is now commercially available with Butterfly's Ultrasound-on-Chip imaging technology. Focalist combines handheld robotics, real-time imaging and guidance software to support image-guided needle procedures, including vascular access, regional nerve blocks and organ access. It is also the first product from Butterfly Embedded, Butterfly's licensing and co-development programme, to reach the market. Both companies are exhibiting at the American College of Emergency Physicians' ACEP26 Scientific Assembly in Chicago from 5 to 7 October.
Mendaera describes itself as building a new category of handheld robotics, and its leadership team's track record includes Auris Health. Unlike Carlsmed and Neuromod, Mendaera's news this week is a launch rather than a hire, but it shows the same category-building challenge from another angle. Surgical robotics has traditionally been sold to surgeons and operating room leaders. Focalist targets needle procedures that are performed across many specialties and settings, as the anaesthesiologist quoted in the launch and the choice of an emergency medicine congress both suggest.
That changes the commercial model. A handheld robot sold across several departments needs capital equipment sales representatives who are comfortable outside the operating room, clinical educators who can train clinicians on image-guided procedures, and partnership or alliance managers who can coordinate with an imaging partner such as Butterfly. For candidates, experience selling point-of-care ultrasound or vascular access products into emergency and anaesthesia teams may now transfer directly into robotics.
On 1 October 2026, Neuromod Devices appointed Joe Ghiz as Chief Commercial Officer and Shannon Basham as Vice President of Channel Development. Neuromod, which has offices in Ireland and North America, said the appointments support its effort to expand access to its Lenire tinnitus treatment through ENT and audiology practices in the United States and other markets.
Ghiz joins from Align Technology, where he held several global commercial leadership positions and served as General Manager of Sales, working to expand adoption of clear aligner treatment and to develop new commercial models for orthodontic practices. Before Align, he spent more than a decade at Johnson & Johnson Vision Care in sales, marketing and business development, including work with independent optometry practices and the ACUVUE contact lens business. At Neuromod, he will lead the global commercial function.
Basham brings more than 20 years in hearing care. She most recently served as Senior Director of Audiology and Education for Sonova in the US, acting as the market-facing head of audiology for the Phonak and Unitron wholesale businesses. Before that, she spent roughly a decade as Director of Clinical Training for Phonak and, earlier, managed the national training team at InSound Medical during the commercialisation of the Lyric hearing aid. InSound Medical was later acquired by Sonova.
Lenire combines sound delivered through headphones with mild electrical stimulation of the tongue. It is prescribed by a qualified healthcare professional after an audiological assessment and then used by the patient at home. It received a De Novo grant from the FDA, is available in the US, Canada, Europe and Australia, and is offered through the US Department of Veterans Affairs.
The Invisalign parallel is deliberate. Neuromod's CEO, Dr Ross O'Neill, pointed to Ghiz's role in helping Align create a new aligner category that changed how orthodontists and dentists practise. Lenire faces a similar route to market: each ENT or audiology practice has to adopt the treatment, fit it into its workflow and offer it to patients. That makes practice development and clinical training as important as the sale itself, which is exactly the experience Basham brings. Companies following this model are likely to look for practice development representatives, audiology-trained clinical trainers, channel managers and regional sales leaders, particularly people who have built adoption inside dental, vision or hearing care practices.
Read together, this week's moves point to three capabilities that category creators cannot do without, and each one has a hiring consequence.
The first is market development. When a product is new, there is no existing demand to capture, so it has to be created account by account. Neuromod's decision to hire a commercial leader who built new models for orthodontic practices, and a channel leader from hearing care, shows that the ability to recruit and activate practices is now valued as highly as the ability to close deals. In US MedTech, that means more demand for practice development, account development and channel roles, and for sales leaders who have taken a product from early adopters to broad use.
The second is clinical education. A new category usually asks clinicians to learn something unfamiliar, whether that is planning a personalised spine procedure, guiding a needle with a handheld robot or prescribing a home-use tinnitus treatment. Basham's career has been built largely in clinical training, and Carlsmed's own reimbursement announcement in August named medical education as a company focus. Clinical educators, clinical specialists and field trainers are not support roles in this model; they are a core part of how the market is built.
The third is reimbursement and market access. Carlsmed's new MS-DRGs show that a favourable payment decision can arrive after a product is already on the market, and that it needs people who can explain it to hospitals once it does. Reimbursement managers, health economics and outcomes research specialists, and market access leads who can speak to hospital finance and value analysis teams are becoming part of the commercial team rather than a separate back-office function.
There is also a fourth, quieter signal: product and commercial leadership are converging. Jarc's remit at Carlsmed covers both the development and the commercialisation of its platform. For AI-enabled devices, the people who design the software and the people who sell its value increasingly need to work as one team.
For hiring managers at early-commercial US MedTech companies, the lesson from Carlsmed and Neuromod is that the most useful experience may sit outside your own therapy area. Neuromod looked to dental, orthodontic and vision care for its commercial lead because those markets share its route to market: adoption built practice by practice. Mendaera's launch suggests that point-of-care ultrasound and vascular access sales experience may matter more to a handheld robotics company than traditional surgical robotics experience. Hiring for the shape of the commercial challenge, rather than the product category alone, widens the talent pool and often brings in people who have already solved the same problem.
For candidates, the profiles in demand are those that can show they have built something rather than inherited it: launching a product, opening a new customer type, training clinicians on an unfamiliar technology or making the case for reimbursement. Commercial professionals from Align, Intuitive, Sonova and similar category builders carry that experience, but so do people from smaller companies that have taken a new technology through its first years of adoption.
44 International works with US MedTech companies hiring across sales, market development, clinical education and market access. If you are building a new category, or are a commercial professional who has done it before, we would be glad to talk.
© All rights reserved